These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 12733726)
41. Zoledronic acid for Paget's disease of bone. Maricic M Drugs Today (Barc); 2007 Dec; 43(12):879-85. PubMed ID: 18174973 [TBL] [Abstract][Full Text] [Related]
42. Comparison of methods of assessing response of Paget's disease to bisphosphonate therapy. Patel S; Coupland CA; Stone MD; Hosking DJ Bone; 1995 Feb; 16(2):193-7. PubMed ID: 7756047 [TBL] [Abstract][Full Text] [Related]
43. Current treatment approaches for Paget's Disease of Bone. Brandi ML Discov Med; 2010 Sep; 10(52):209-12. PubMed ID: 20875342 [TBL] [Abstract][Full Text] [Related]
44. Long-Term Effects of Intravenous Ibandronate in Paget's Disease of Bone. Reid IR; Wattie D; Gamble GD; Kalluru R; Cundy T Calcif Tissue Int; 2017 Mar; 100(3):250-254. PubMed ID: 27866237 [TBL] [Abstract][Full Text] [Related]
45. The use of zoledronic acid for Paget's disease of bone. Maricic M Curr Osteoporos Rep; 2006 Mar; 4(1):40-4. PubMed ID: 16527007 [TBL] [Abstract][Full Text] [Related]
46. Pathogenesis and management of Paget's disease of bone. Ralston SH; Langston AL; Reid IR Lancet; 2008 Jul; 372(9633):155-163. PubMed ID: 18620951 [TBL] [Abstract][Full Text] [Related]
47. Zoledronic acid: a review of its use in the treatment of Paget's disease of bone. Keating GM; Scott LJ Drugs; 2007; 67(5):793-804. PubMed ID: 17385948 [TBL] [Abstract][Full Text] [Related]
48. [Therapy of Paget's disease]. Kurth AA Orthopade; 2007 Feb; 36(2):118, 120-3. PubMed ID: 17252256 [TBL] [Abstract][Full Text] [Related]
49. Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid. Polyzos SA; Anastasilakis AD; Anagnostis P; Kita M; Arsos G; Moralidis E; Papatheodorou A; Terpos E Endokrynol Pol; 2012; 63(4):312-5. PubMed ID: 22933168 [TBL] [Abstract][Full Text] [Related]
50. Radiological assessment of Paget's disease of bone after treatment with the bisphosphonates EHDP and APD. Dodd GW; Ibbertson HK; Fraser TR; Holdaway IM; Wattie D Br J Radiol; 1987 Sep; 60(717):849-60. PubMed ID: 3117159 [TBL] [Abstract][Full Text] [Related]
51. The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone. Garnero P; Christgau S; Delmas PD Bone; 2001 May; 28(5):461-4. PubMed ID: 11344044 [TBL] [Abstract][Full Text] [Related]
52. Acquired resistance to bisphosphonates in Paget's disease of bone. Papapoulos SE; Eekhoff EM; Zwinderman AH J Bone Miner Res; 2006 Dec; 21 Suppl 2():P88-91. PubMed ID: 17229015 [No Abstract] [Full Text] [Related]
53. Paget's disease of bone: clinical, pathogenetic and therapeutic aspects. Papapoulos SE Baillieres Clin Endocrinol Metab; 1997 Apr; 11(1):117-43. PubMed ID: 9222489 [TBL] [Abstract][Full Text] [Related]
54. Short-term therapy with oral olpadronate in active Paget's disease of bone. González DC; Mautalen CA J Bone Miner Res; 1999 Dec; 14(12):2042-7. PubMed ID: 10620063 [TBL] [Abstract][Full Text] [Related]
55. Quantitative bone scintigraphy in the management of monostotic Paget's disease of bone. Patel S; Pearson D; Hosking DJ Arthritis Rheum; 1995 Oct; 38(10):1506-12. PubMed ID: 7575701 [TBL] [Abstract][Full Text] [Related]
56. Serum kinetics, bioavailability and bone scanning of 99mTc-labelled sodium olpadronate in patients with different rates of bone turnover. Degrossi OJ; Ortiz M; Degrossi EB; García del Río H; Barreira JC; Messina D; Kerzberg E; Roldán EJ; Montuori E; Pérez Lloret A Eur J Clin Pharmacol; 1995; 48(6):489-94. PubMed ID: 8582468 [TBL] [Abstract][Full Text] [Related]
57. Paget's disease of bone: diagnosis and treatment update. Noor M; Shoback D Curr Rheumatol Rep; 2000 Feb; 2(1):67-73. PubMed ID: 11123042 [TBL] [Abstract][Full Text] [Related]
58. Paget's disease of bone. Cundy T Metabolism; 2018 Mar; 80():5-14. PubMed ID: 28780255 [TBL] [Abstract][Full Text] [Related]
59. Relapse of osteoporosis circumscripta as a lytic ring after treatment of Paget's disease with intravenous 3-amino-1-hydroxypropylidene-1,1-bisphosphonate. Anderson DC; O'Driscoll JB; Buckler HM; Cantrill J; Brown JD Br J Radiol; 1988 Nov; 61(731):996-1001. PubMed ID: 3208019 [TBL] [Abstract][Full Text] [Related]